Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based pharmaceutical firm BioQuiddity has signed an exclusive license and supply agreement with Sandoz, a division of Novartis, to commercialize two ready-to-use infusion products in the US.
Subscribe to our email newsletter
Under the deal, BioQuiddity will secure the requisite regulatory approvals and supplying the unit-dose infusion systems, while Sandoz is responsible to market and commercialize BioQuiddity’s ropivacaine and propofol infusion pharmaceutical products.
BioQuiddity president and CEO Josh Kriesel said: "We are thrilled to collaborate with Sandoz, a proven leader in the healthcare industry.
"Our ready-to-use drug delivery platform provides a therapy specific solution that is immediately deployable at the point of care without multiple preparation steps.
"We look forward to rapidly offering a portfolio of innovative cost effective infusion solutions in the US through this collaboration."
BioQuiddity’s infusion platform addresses some of the most pressing unmet needs in drug infusion including cost, medication error, sterility, efficiency and patient quality of life.